Becton, Dickinson and Company (BDX) Shares Sold by Paloma Partners Management Co

Paloma Partners Management Co reduced its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 56.1% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 28,821 shares of the medical instruments supplier’s stock after selling 36,760 shares during the period. Paloma Partners Management Co’s holdings in Becton, Dickinson and were worth $5,287,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Beese Fulmer Investment Management Inc. raised its position in Becton, Dickinson and by 2.7% in the first quarter. Beese Fulmer Investment Management Inc. now owns 26,022 shares of the medical instruments supplier’s stock valued at $4,773,000 after buying an additional 688 shares during the period. Wealth Enhancement Advisory Services LLC raised its position in Becton, Dickinson and by 188.1% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 26,494 shares of the medical instruments supplier’s stock valued at $4,881,000 after buying an additional 17,298 shares during the period. Carderock Capital Management Inc. raised its position in Becton, Dickinson and by 0.5% in the first quarter. Carderock Capital Management Inc. now owns 13,499 shares of the medical instruments supplier’s stock valued at $2,476,000 after buying an additional 69 shares during the period. Pinnacle Bank bought a new position in Becton, Dickinson and during the first quarter valued at approximately $192,000. Finally, Doyle Wealth Management bought a new position in Becton, Dickinson and during the first quarter valued at approximately $434,000. Hedge funds and other institutional investors own 75.71% of the company’s stock.

Becton, Dickinson and Company (BDX) traded up 0.9235% during trading on Friday, reaching $200.0506. The company had a trading volume of 291,062 shares. The firm has a 50-day moving average price of $198.75 and a 200 day moving average price of $187.49. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $206.63. The stock has a market cap of $45.52 billion, a P/E ratio of 57.9353 and a beta of 1.05.

Becton, Dickinson and (NYSE:BDX) last released its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.44 by $0.02. The firm had revenue of $3.04 billion during the quarter, compared to analyst estimates of $3.06 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The business’s revenue was down 5.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.35 EPS. Equities research analysts predict that Becton, Dickinson and Company will post $9.46 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Shareholders of record on Friday, September 8th will be given a dividend of $0.73 per share. This represents a $2.92 dividend on an annualized basis and a yield of 1.47%. The ex-dividend date is Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio is 83.43%.

TRADEMARK VIOLATION WARNING: This piece was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States & international copyright and trademark law. The legal version of this piece can be accessed at https://www.com-unik.info/2017/08/11/becton-dickinson-and-company-bdx-shares-sold-by-paloma-partners-management-co.html.

BDX has been the topic of several research reports. BidaskClub lowered Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Bank of America Corporation reissued a “buy” rating and issued a $225.00 price objective (up from $200.00) on shares of Becton, Dickinson and in a research report on Friday, July 21st. Zacks Investment Research raised Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price objective on the stock in a research report on Monday, July 17th. Stifel Nicolaus reissued a “buy” rating on shares of Becton, Dickinson and in a research report on Wednesday. Finally, Barclays PLC reissued an “equal weight” rating and issued a $210.00 price objective (up from $205.00) on shares of Becton, Dickinson and in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $195.79.

In other Becton, Dickinson and news, insider Thomas E. Polen, Jr. sold 5,971 shares of the business’s stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the completion of the transaction, the insider now owns 12,861 shares of the company’s stock, valued at approximately $2,538,890.01. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Jeffrey S. Sherman sold 28,765 shares of the business’s stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $185.98, for a total transaction of $5,349,714.70. Following the transaction, the vice president now directly owns 70,821 shares of the company’s stock, valued at approximately $13,171,289.58. The disclosure for this sale can be found here. 1.40% of the stock is owned by insiders.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

What are top analysts saying about Becton Dickinson and Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Becton Dickinson and Company and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit